BrightPath Biotherapeutics Co., Ltd.
1 clinical trials · Sponsor
◉ Watch BrightPath Biotherapeutics Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma (NCT07667868) | BrightPath Biotherapeutics Co., Ltd. | 2026-10-01 |
Track BrightPath Biotherapeutics Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.